Racial disparities in omission of oncotype DX but no racial disparities in chemotherapy receipt following completed oncotype DX test results.

about

Racial disparities in omission of oncotype DX but no racial disparities in chemotherapy receipt following completed oncotype DX test results.

Item

http://www.wikidata.org/entity/Q48225891

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Racial disparities in omission ...... eted oncotype DX test results.

@en

Racial disparities in omission ...... eted oncotype DX test results.

@nl

type

Item

label

Racial disparities in omission ...... eted oncotype DX test results.

@en

Racial disparities in omission ...... eted oncotype DX test results.

@nl

prefLabel

Racial disparities in omission ...... eted oncotype DX test results.

@en

Racial disparities in omission ...... eted oncotype DX test results.

@nl

P1476

Racial disparities in omission ...... leted oncotype DX test results

@en

P2093

Abiola Ibraheem

http://www.w3.org/2001/XMLSchema#string

Dezheng Huo

http://www.w3.org/2001/XMLSchema#string

Kathleen H Goss

http://www.w3.org/2001/XMLSchema#string

M Eileen Dolan

http://www.w3.org/2001/XMLSchema#string

Suzanne Conzen

http://www.w3.org/2001/XMLSchema#string

P2860

The impact of the Oncotype Dx breast cancer assay in clinical practice: a systematic review and meta-analysis

The concept of synthetic lethality in the context of anticancer therapy

The black:white disparity in breast cancer mortality: the example of Chicago

A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer

A new method of classifying prognostic comorbidity in longitudinal studies: development and validation

American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer

Utilization and impact of 21-gene recurrence score assay for breast cancer in clinical practice across the United States: lessons learned from the 2010 to 2012 National Cancer Data Base analysis.

The National Cancer Data Base: a powerful initiative to improve cancer care in the United States

American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer.

Comparison of commission on cancer-approved and -nonapproved hospitals in the United States: implications for studies that use the National Cancer Data Base.

P2888

s10549-017-4587-8

P304

207-220

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S10549-017-4587-8

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

168

http://www.w3.org/2001/XMLSchema#string

P50

David J Press

P577

2017-11-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29181717

http://www.w3.org/2001/XMLSchema#string